New trial aims to find safer chemo for stem cell transplants in leukemia patients

NCT ID NCT07025824

Not yet recruiting Disease control Sponsor: Technische Universität Dresden Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests two chemotherapy drugs, treosulfan and melphalan, given before a stem cell transplant in 220 adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to see which drug works better at helping patients survive longer with fewer side effects. Participants will receive one of the two drugs along with fludarabine, and researchers will track survival, remission, and complications like graft-versus-host disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Treosulfan and Melphalan (chemotherapy drugs)
What this could lead to: If it works, this could show that treosulfan is a better option than melphalan for preparing patients with AML or MDS for a stem cell transplant, potentially improving survival and reducing complications.
What could go wrong: This is a phase 2 trial with 220 participants, so results are still early. The drugs may cause serious side effects like infections or graft-versus-host disease, and the study may not show a clear benefit for treosulfan.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome myelodysplastic syndrome with excess blasts

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML (ACUTE MYELOID LEUKEMIA) MDS (MYELODYSPLASTIC SYNDROME)

Contacts and locations

Locations

Medizinische Fakultät der TU Dresden, Medizinische Klinik und Poliklinik I

Dresden, Germany
Universitätsklinikum Münster, Medizinische Klinik A, KMT-Zentrum

Münster, Germany
Universitätsklinikum Schleswig-Holstein, Campus Kiel

Kiel, Germany
Universitätsmedizin Halle (Saale)

Halle, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.